title: Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy.
authors: Cancer Research Campaign Laboratories, Department of Medical Oncology, Charing Cross Hospital, London, UK.
authors: D B
authors: DB
authors: Smith
authors: E S
authors: ES
authors: Newlands
authors: O W
authors: OW
authors: Spruyt
authors: R H
authors: RH
authors: Begent
authors: G J
authors: GJ
authors: Rustin
authors: B
authors: B
authors: Mellor
authors: K D
authors: KD
authors: Bagshawe
mesh_terms: D000293:Adolescent; D000328:Adult; D000932:Antiemetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003907:Dexamethasone / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D009325:Nausea / Q000517:prevention & control; D017294:Ondansetron; D012702:Serotonin Antagonists; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control
chemical_list: D000932:Antiemetics; D007093:Imidazoles; D012702:Serotonin Antagonists; D017294:Ondansetron; D003907:Dexamethasone